Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer
Go back to Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 14.69 -0.36 (2.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.05 | 52 Week High | $19.40 | |||
| Open | $15.05 | 52 Week Low | $12.50 | |||
| Day High | $15.40 | P/E | N/A | |||
| Day Low | $14.67 | EPS | $0.00 | |||
| Volume | 100,627 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 27.79 -0.66 (2.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.45 | 52 Week High | $37.39 | |||
| Open | $28.01 | 52 Week Low | $28.25 | |||
| Day High | $28.15 | P/E | 16.84 | |||
| Day Low | $27.72 | EPS | $1.65 | |||
| Volume | 31,756,884 | |||||
